Rakovina Therapeutics Inc
Research Rakovina Therapeutics Inc (RKV) on Bullrun: market cap CAD 3.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRKV
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 3.66M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 1.68M
- Free cash flow-CAD 712.85K
Valuation Snapshot
latest market cap is CAD 3.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 8.77M | -CAD 5.82M | n/a | n/a | CAD 298.76K | CAD 2.60M | CAD 139.73K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | CAD 3.66M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rakovina Therapeutics Inc's market cap?
Rakovina Therapeutics Inc's market capitalization is CAD 3.66M.
What does Rakovina Therapeutics Inc do?
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells.